Metronidazole-containing gel for the treatment of periodontitis: an in vivo evaluation by SATO, Sandra et al.
Periodontics
Braz Oral Res 2008;22(2):145-50 145
Metronidazole-containing gel for  
the treatment of periodontitis:  
an in vivo evaluation
Abstract: The aim of this investigation was to monitor metronidazole 
concentrations in the gingival crevicular fluid (GCF) collected from peri-
odontal pockets of dogs after treatment with an experimental 15% met-
ronidazole gel. Five dogs had periodontitis induced by cotton ligatures 
placed subgingivally and maintained for a 30-day period. After the in-
duction period, only pockets with 4 mm or deeper received the gel. Each 
pocket was filled up to the gingival margin by means of a syringe with 
a blunt-end needle. GCF was collected in paper strips and quantified in 
an electronic device before and after 15 minutes, 1 h, 6 h, 24 h and 48 h 
of gel administration. The GCF samples were assayed for metronidazole 
content by means of a high performance liquid chromatography method. 
Concentrations of metronidazole in the GCF of the 5 dogs (mean ± SD, 
in µg/mL) were 0 ± 0 before gel application and 47,185.75 ± 24,874.35 
after 15 minutes, 26,457.34 ± 25,516.91 after 1 h, 24.18 ± 23.11 after 6 
h, 3.78 ± 3.45 after 24 h and 3.34 ± 5.54 after 48 h. A single administra-
tion of the 15% metronidazole gel released the drug in the GCF of dogs 
in levels several-fold higher than the minimum inhibitory concentration 
for some periodontopathogens grown in subgingival biofilms for up to 
one hour, but metronidazole could be detected in the GCF at least 48 
hours after the gel application.
Descriptors: Periodontitis; Metronidazole; Drug delivery systems.
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Introduction
Bacteriological studies show that most, if not all, 
forms of periodontal disease are infections caused 
by the overgrowth of a limited number of typically 
Gram-negative anaerobic microorganisms.1 Several 
approaches to treat periodontitis have been focusing 
on the reduction or eradication of specific periodontal 
pathogens. These approaches are based on the system-
ic2 or local administration3,4 of antimicrobial agents.
The systemic use of antibiotics raises a number 
of issues. A prolonged administration increases the 
risk of problems such as antibiotic resistance5 and 
adverse drug reactions like nausea, diarrhea and 
pseudomembranous colitis.2 As a result of these 
matters, studies focusing on the development of lo-
calized drug delivery systems for the release of an-
tibiotics in the periodontal pockets are becoming 
more frequent. This approach leads to higher con-
centrations of the drug at the target sites, minimiz-
ing the potential systemic side effects.4
Local delivery of antimicrobials in periodontal 
pockets may be carried out with fibers, films, mic-
roparticles and gels made of biodegradable or non-
degradable polymers and have been proposed as ef-
fective methods to administer antimicrobial agents 
in periodontal therapy.3
One class of hydrogels used for controlled re-
lease of drugs in many pharmaceutical applications 
is represented by the poloxamers, which are non-
ionic poly(ethylene oxide)-poly(propylene oxide)-
poly(ethylene oxide) triblock copolymers. Polox-
amer 407 has been one of the most extensively used 
copolymers. It has low toxicity, is compatible with 
other chemicals and can solubilize drugs with differ-
ent physicochemical properties. Additionally, aque-
ous solutions of poloxamer 407, at concentrations 
of 20% and above, demonstrate a thermoreversible 
gelation behaviour, characterized by a critical tem-
perature. At temperatures under the critical one, the 
poloxamer solution is in the form of a low-viscosity 
sol, while above it, when approaching body temper-
ature, a viscous transparent gel is formed.6
Among the antimicrobials used for the treatment 
of periodontitis, metronidazole is particularly suit-
able due to its restricted spectrum of activity against 
obligate anaerobes7 and its limited side effects, com-
pared to those of tetracyclines, i.e., selection of mul-
tiresistant bacteria8 and perturbation of the normal 
microbiota of the body.
In a previous study, a poloxamer 407 gel con-
taining 15% of metronidazole was formulated and 
tested in vitro in a device that simulated the con-
ditions of humidity, temperature and gingival fluid 
flow of a periodontal pocket. It was demonstrated 
that metronidazole could be released in a sustained 
manner for at least 7 days.9
Since promising results were obtained in vitro9 
the purpose of the present study was to evaluate this 
poloxamer gel, in vivo, by monitoring the metroni-
dazole concentrations in the gingival crevicular fluid 
of dogs with induced periodontitis.
Materials and Methods
This study was approved by the local Ethics Com-
mittee for Animal Usage (process # 04.1.475.53.7).
Five mongrel dogs (2 males, 3 females), 3-4 years of 
age and weighing 10-15 kg, were used in this study. All 
the procedures in the animals were performed under 
general anesthesia. Periodontitis was induced accord-
ing to Nociti Jr. et al.10 (2001). Cotton ligatures were 
placed subgingivally around the test teeth (upper and 
lower incisors and premolars). Each dog had 6 teeth 
ligated, resulting in a total of 30 teeth in which the for-
mation of periodontal pockets was induced. During 30 
days, the ligatures were left in place and the dogs were 
fed a soft diet to promote plaque accumulation. After 
the ligation period, only pockets with probing depth of 
at least 4 mm were used for gel application.
Poloxamer gel was prepared according to the cold 
technique.11 The formulation used in this study consist-
ed of poloxamer 407 30% w/w (BASF, Ludwigshafen, 
Germany), propyleneglycol 5% w/w (Labsynth, Di-
adema, SP, Brazil), methylparaben 0.15% w/w (Lab-
synth), metronidazole 15% w/w (Formil Química, 
Jandira, SP, Brazil) and distilled water to 100%. 
The gel was administered by means of a syringe 
with a bent, blunt-end needle. The needle was care-
fully inserted into the periodontal pocket and the gel 
was applied in the test sites in a gentle probing man-
ner, attempting to fill the full extent of the pocket. 
Gel was applied up to the gingival margin, and the 
excess of gel was removed with a sterile gauze.
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GCF samples were obtained from the test sites be-
fore gel administration and after 15 minutes, 1 hour, 
6 hours, 24 hours and 48 hours of gel application. 
Before the collection of GCF, supragingival biofilm 
was removed with a gauze. The teeth were isolated 
with sterile gauzes and the areas around the gingival 
crevice were gently dried with an air syringe. Filter 
paper strips (Oraflow, Plainview, NY, USA) were in-
troduced into the gingival crevice for a period of 5 
seconds. Upon removal, the volume of GCF on the 
paper strip was measured on a precalibrated Peri-
otron 8000 (Oraflow). The GCF of each periodontal 
pocket was sampled with two paper strips that were 
pooled into a microtube containing 500 µl of a mix-
ture of methanol:water (30:70; v/v). The paper strips 
were rejected if contaminated by blood or saliva.
The microtubes with the paper strips were vor-
tex mixed for 2 minutes. Each GCF sample passed 
through a filter of 0.45 µm and 13 mm (Millipore, 
São Paulo, SP, Brazil) prior to injection of an ali-
quot of 20 µl into the HPLC system. The system 
was a LC-10AT (Shimadzu, Tokyo, Japan) equipped 
with a 20 µl loop and a SPD-10A UV/VIS detector 
(λ = 320 nm). Integration of the chromatographic 
peaks was achieved using a C-R6A Chromatopac 
integrator (Shimadzu). Chromatographic separation 
was performed using a Nova-Pak C18 column (par-
ticle size: 4 µm, 300 x 3.9 mm; Waters, Milford, 
MA, USA), with methanol:water (30:70; v/v) as mo-
bile phase and flow rate adjusted at 1 ml/min.
Metronidazole concentrations in GCF were cal-
culated by averaging the values obtained for each 
site that received the metronidazole-containing gel 
within each dog, and then averaged among the 5 
dogs. Data were summarized with descriptive sta-
tistics (mean, standard deviation) using the software 
NCSS 2001 (NCSS, Kaysville, UT, USA).
Results
From the total of 30 teeth that had induced peri-
odontitis, 28 achieved the minimum established 
probing depth of at least 4 mm and were included 
in the study.
The measurements from the paper strips loaded 
with GCF during sampling were converted to micro-
liter values, and the volume of GCF collected from 
the periodontally involved sites ranged between 
0.25 µL and 1.24 µL.
Metronidazole gel showed an initial burst release, 
with large concentrations of the drug found in GCF 
at 15 minutes and 1 hour after the gel administration, 
decreasing rapidly after 6 hours and found at low 
concentrations at 24 and 48 hours of application.
Table 1 shows mean metronidazole concentra-
Table 1 - Means and standard deviation (SD) of metronidazole concentrations (in µg/mL) in the gingival crevicular fluid of 5 
dogs with induced periodontitis before and after various times (in hours) of gel application.
Time
(hours)
Animal Mean
(5 dogs)1 (6 sites) 2 (5 sites) 3 (6 sites) 4 (5 sites) 5 (6 sites)
before
Mean 0 0 0 0 0 0
SD 0 0 0 0 0 0
0.25
Mean 27,154.60 79,378.04 18,492.30 49,232.17 61,671.62 47,185.75
SD 5,892.50 12,557.18 10,422.01 11,245.82 17,430.75 24,874.35
1
Mean 4,817.07 68,129.56 6,500.07 25,619.81 27,220.20 26,457.34
SD 4,814.77 34,478.24 8,149.60 25,034.10 32,024.44 25,516.91
6
Mean 24.95 7.54 0 28.83 59.56 24.18
SD 40.00 4.61 0 39.90 105.37 23.11
24
Mean 0.58 7.84 0 4.12 6.35 3.78
SD 1.00 6.38 0 5.89 8.05 3.45
48
Mean 0 12.77 0 0 3.90 3.34
SD 0 5.35 0 0 6.10 5.54
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tions in the GCF samples taken before and up to 48 
hours after gel application. The detection and quan-
tification limits were 0.2 ng/mL and 3.4 ng/mL, re-
spectively. Metronidazole was not detected before 
gel application in the GCF samples. The drug levels 
were above the quantification limit in all samples 
after 15 minutes and after one hour of gel admin-
istration and in 78.57% (22/28 sites) after 6 hours, 
39.29% (11/28) after 24 hours and in 25% (7/28) 
after 48 hours. No GCF samples had detectable 
metronidazole beyond 48 hours, as formerly ob-
served in a pilot study (unpublished result).
Discussion
Poloxamers are commercially available non-ionic 
macromolecular surface active agents that have at-
tracted substantial interest in the biotechnological 
and pharmaceutical fields for their unique surfac-
tant, thermogelling and bioadhesive properties, low 
toxicity and minimal immune response.12
Formulations based in poloxamer 407 had al-
ready demonstrated to be appropriate for delivery of 
tetracycline in periodontal pockets.13 The biocom-
patibility and easy elimination from the body and 
characteristics such as low viscosity at the moment 
of administration were the reasons to use this poly-
mer to formulate a gel, metronidazole-based, for the 
treatment of periodontitis. It was demonstrated, in a 
preliminary study, that this poloxamer gel released 
metronidazole for a period of 7 days in vitro.9
In the present in vivo investigation, metronida-
zole released by the poloxamer gel was detected for 
a maximum period of 48 hours after a single appli-
cation, and only in two of the five dogs of the study. 
This period is less than the 7 days obtained in vitro 
by Gabarra9 (2002), but is in agreement with Sos-
nik, Cohn14 (2004), who demonstrated that a gel 
containing 30% of poloxamer 407, the same con-
centration of the polymer used in our study, deliv-
ered in vitro all the metronidazole within 2 days.
Metronidazole levels in GCF were assessed by 
high performance liquid chromatography, as this 
method was found to be appropriate for this pur-
pose.15 The technique used for GCF sampling al-
lowed the determination of the volume of GCF 
collected, as it varied among sites, and permitted a 
proper estimation of metronidazole concentration 
by milliliter of GCF in the pockets at the time of 
sampling.16
The principal information required from an in 
vivo study with local delivery systems is if there is 
retention within the periodontal pockets of the final 
product, with therapeutic drug levels established and 
maintained at the diseased sites for a period that is 
adequate to suppress microbial activity, with conse-
quent benefit in the treatment of periodontitis.17
The determination of the accurate drug concen-
tration that has to be maintained in the gingival cre-
vicular fluid for a periodontitis therapy to be suc-
cessful is not straightforward. Normally, antibiotic 
treatment should achieve drug levels in infected tis-
sues at least equal to the minimal inhibitory concen-
tration (MIC) of the targeted microorganism.
In periodontitis lesions, some of the most com-
monly found bacteria are Gram-negative anaerobic 
rods, such as Porphyromonas gingivalis and Pre-
votella intermedia.18 The MIC of metronidazole 
against P. gingivalis, determined in some in vitro 
studies, did not exceed 1 µg/mL.18 P. intermedia 
was found to have MIC up to 8 µg/mL.19 It is im-
portant to remember that these susceptibility tests 
are generally performed with planktonic bacterial 
cells. However, in periodontal pockets, microorgan-
isms are organized in biofilms, and it is known that 
subgingival bacteria in biofilms are more resistant to 
antimicrobial treatment.20 Eick et al.21 (2004) found 
that, while planktonic cells of P. gingivalis were sus-
ceptible to only 1 µg/mL of metronidazole, the elim-
ination of this anaerobe grown within an artificial 
biofilm of this single species was only achieved with 
concentrations of 100-fold the MIC for planktonic 
organisms, or 100 µg/mL of the drug. The men-
tioned investigation may be regarded as an estimate 
of the necessary metronidazole concentration neces-
sary for the eradication of a microorganism associat-
ed in a biofilm, but it can not be considered the real 
MIC for this bacterium in a subgingival biofilm be-
cause the in vitro conditions may not represent with 
fidelity what happens in a real periodontal pocket.
Studies show that the concentration of metroni-
dazole released in the GCF after systemic use might 
be enough to inhibit bacteria in planktonic form, 
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but not the ones within biofilms. Britt, Pohlod15 
(1986) found a peak concentration of 3.62 µg/mL of 
the drug after a single oral dose of 250 mg of met-
ronidazole. Van Oosten et al.22 (1986) found peak 
concentrations after a single dose of 750 mg of met-
ronidazole taken orally ranging from 8.7 µg/mL to 
13.8 µg/mL in the gingival crevice. Pahkla et al.23 
(2005) found mean GCF levels of approximately 
13 µg/mL of metronidazole after two hours of sys-
temic use.23 In comparison to systemic use, local de-
livery devices, such as the one presented here, are 
advantageous because of the ability of releasing an-
timicrobial agents in concentrations high enough to 
affect pathogens, even in subgingival biofilms.
Although a short residence time of the antibi-
otic into periodontal pockets might be a predictor 
of poor performance of a local delivery system, 
only the evaluation of clinical and microbiological 
parameters would be able to show if the concentra-
tions released and the time of drug delivery inside 
the pockets were enough for a successful treatment 
of periodontitis. As an example, a commercially 
available gel may be cited containing 25% of metro-
nidazole, which could release the drug for no more 
than 36 hours.16 While some studies with this gel 
demonstrated improvements in clinical and micro-
biological parameters of periodontitis after subgin-
gival application as a monotherapy24 or when as-
sociated with conventional mechanical therapy,25-27 
others did not observe such advantages in the use of 
this association.28-30
Studies to assess the effects of this gel on clini-
cal and microbiological parameters of periodontitis 
are currently being conducted and the results will 
complement the evaluation of this thermoreversible 
gel as a local delivery system for periodontitis treat-
ment.
Conclusion
It was demonstrated that, after a single admin-
istration of the experimental gel into periodontal 
pockets of dogs, metronidazole could be released in 
the GCF in concentrations several-fold higher than 
the MIC for periodontal pathogens grown in sub-
gingival biofilms for up to one hour and that the 
drug could be found above the quantification limit 
for at least 48 hours.
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